logo
logo
Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

NASDAQ•AUPH
CEO: Mr. Peter S. Greenleaf M.B.A.
セクター: Healthcare
業種: Biotechnology
上場日: 2014-09-03
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
連絡先情報
118 Avenue , 14315, Suite 140, Edmonton, AB, T5L 4S6, Canada
250-744-2487
www.auriniapharma.com
時価総額
$1.88B
PER (TTM)
25.1
34.3
配当利回り
--
52週高値
$16.54
52週安値
$6.55
52週レンジ
77%
順位56Top 81.7%
2.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$73.47M+8.41%
直近4四半期の推移

EPS

$0.24+140.00%
直近4四半期の推移

フリーCF

$44.38M+161.94%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Net Income Soars Nine months net income reached $76.41M USD, a massive increase from $4.32M USD in 2024, driven by strong sales growth.
Total Revenue Increased Total revenue for nine months was $205.94M USD, growing 17.5% from $175.27M USD, fueled by LUPKYNIS product sales.
Operating Cash Flow Strong Cash flow from operations was $89.99M USD for nine months, significantly up from $14.27M USD in the prior year period.
SG&A Expenses Reduced Nine months SG&A expense dropped $62.46M USD to $72.54M USD, reflecting benefits realized from 2024 strategic restructuring efforts.

リスク要因

LUPKYNIS Patent Defense Facing multiple Paragraph IV ANDA challenges alleging invalidity of key 2037 Patents protecting LUPKYNIS exclusivity in the U.S. market.
Defamation Lawsuit Filed Company filed suit against Dr. Tidmarsh for defamation and injurious falsehood regarding voclosporin statements on November 2, 2025.
Increased R&D Spending Nine months R&D expense rose $8.93M USD to $21.61M USD, expected to increase further for continued development activities ahead.
Potential Financing Needs Future funding needs depend on LUPKYNIS success; company may raise additional capital via equity or debt financings if necessary.

見通し

Aritinercept Clinical Progress Announced positive Phase 1 results for aritinercept; plans clinical studies in two autoimmune diseases by the end of 2025.
Realizing Restructuring Benefits Restructuring activities substantially completed in H1 2025; expects SG&A expense to remain lower compared to 2024 results.
Share Repurchase Activity Board approved $150M increase to Share Repurchase Plan; repurchased $98.16M USD worth of common shares year to date.
Continued IP Enforcement Company intends to vigorously enforce intellectual property rights related to LUPKYNIS against generic competitors moving forward.

同業比較

売上高 (TTM)

Novavax, Inc.NVAX
$1.06B
+20.3%
Harmony Biosciences Holdings, Inc.HRMY
$825.94M
+21.1%
BioCryst Pharmaceuticals, Inc.BCRX
$599.82M
+45.4%

粗利益率 (最新四半期)

Zymeworks Inc.ZYME
100.0%
+0.0pp
AbCellera Biologics Inc.ABCL
100.0%
+588.5pp
Immunocore Holdings plcIMCR
99.5%
+0.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EWTX$3.18B-20.1-30.9%0.7%
VERA$2.96B-10.7-50.9%14.9%
HRMY$2.07B11.324.9%14.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
7.1%
安定成長
4四半期純利益CAGR
180.5%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月26日
|
EPS:$0.21
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $73.47M+8.4%
    |
    EPS: $0.24+140.0%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月31日|
    売上高: $70.01M+22.4%
    |
    EPS: $0.16+1500.0%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $62.47M+24.2%
    |
    EPS: $0.16-314.5%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $235.13M+34.0%
    |
    EPS: $0.04+107.4%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $67.77M+24.3%
    |
    EPS: $0.10-206.3%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月1日|
    売上高: $57.19M+37.8%
    |
    EPS: $0.01-112.5%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $50.30M+46.2%
    |
    EPS: $-0.07-58.6%
    予想を上回る

  • Form 10-K/A - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年4月29日|
    売上高: $175.51M+31.0%
    |
    EPS: $-0.54+28.9%
    予想を下回る